VANCOUVER, April 14, 2020 /CNW/ - Sirona Biochem Corp.
(TSX-V: SBM) (FSE: ZSB) (US-OTC: SRBCF) ("Sirona") is
pleased to inform its shareholders that a video interview with its
Chief Scientific Officer, Dr. Géraldine Deliencourt-Godefroy, has
been published by Austrian journalist Joachim Brunner (www.smallcapinvestor.de).
"This interview gives investors great insight into how our
scientific team innovate using our novel platform technology and
why it is important to collaborate with major cosmetic companies at
an early stage, even at planning a first clinical trial. I am very
proud of our scientists and their ability to continually grow our
pipeline", said Dr. Howard Verrico,
CEO of Sirona Biochem.
Here is a short sneak preview in the following Q&A
format:
Q. What makes your (technology) platform so
unique?
A. Usually when you do drug development you have to
do 10,000 of compounds to find one which works. In our technology,
each compound that we target, works… We have to do five compounds
and we are sure to have five active compounds and one of them
becomes more efficient because of bioavailability etc.
Q: What is your (development) focus now?
A. So, we have the anti-wrinkle (compound). It is
working well. We have made some good advance...
Q: What is the next big thing for you?
A. The next big thing is glycoprotein / anti-aging
(compound) where we have a lot of interesting - very big -
prospects and the potential for this compound is just amazing… it's
what all the major cosmetic companies are looking for…
During the interview, further details of the antiviral program,
are provided, some of which have not been previously disclosed. The
antiviral project was already initiated in August 2019, well before the current COVID-19
pandemic was declared. With the current need for new antiviral
compounds and the ability to partner and fund the program,
management has decided to prioritize this project.
Other projects at early stages of research and development
include therapeutic compounds to treat urinary tract infections,
Crohn's disease, anti-inflammatory drugs and anticancer drugs are
now made public. Also, the potential to use existing patented
compounds to treat Non-Alcoholic SteatoHepatitis (NASH) and
conditions resulting in fibrosis are discussed.
"The anti-wrinkle program is progressing nicely with further
studies beginning next week and the potential for a clinical trial
in 2021", added Dr. Howard Verrico,
CEO of Sirona Biochem.
The interview can be viewed at www.youtu.be/vDLtSUR2OC8 or
on Sirona's website www.sironabiochem.com.
On another note, Sirona will be attending the 2020 BIO
International Convention, June 8-12,
2020. The conference will be held virtually and will allow
Sirona to present its technology to key pharmaceutical companies.
Virtual BIO One-on-One Partnering meetings will also take place.
Sirona is adapting to industry changes driven by the evolving
impact of COVID-19. These changes have been seamless for the team
and in many cases have improved the ability to operate
globally.
About Sirona Biochem Corp.
Sirona Biochem is a cosmetic ingredient and drug discovery
company with a proprietary platform technology. Sirona's subsidiary
lab, TFChem, specializes in stabilizing carbohydrate molecules with
the goal of improving efficacy and safety. New compounds are
patented for maximum revenue potential.
Sirona's compounds are licensed to leading companies around the
world in return for licensing fees, milestone fees and ongoing
royalty payments.
For more information, please
visit www.sironabiochem.com.
Neither TSX Venture Exchange nor its Regulation Services
Provider (as that term is defined in policies of the TSX Venture
Exchange) accepts responsibility for the adequacy or accuracy of
this release.
______________________________
Sirona Biochem cautions you that statements included in this
press release that are not a description of historical facts may be
forward-looking statements. Forward-looking statements are only
predictions based upon current expectations and involve known and
unknown risks and uncertainties. You are cautioned not to place
undue reliance on these forward-looking statements, which speak
only as of the date of release of the relevant information, unless
explicitly stated otherwise. Actual results, performance or
achievement could differ materially from those expressed in, or
implied by, Sirona Biochem's forward-looking statements due to the
risks and uncertainties inherent in Sirona Biochem's business
including, without limitation, statements about: the progress and
timing of its clinical trials; difficulties or delays in
development, testing, obtaining regulatory approval, producing and
marketing its products; unexpected adverse side effects or
inadequate therapeutic efficacy of its products that could delay or
prevent product development or commercialization; the scope and
validity of patent protection for its products; competition from
other pharmaceutical or biotechnology companies; and its ability to
obtain additional financing to support its operations. Sirona
Biochem does not assume any obligation to update any
forward-looking statements except as required by law.
SOURCE Sirona Biochem Corp.